Can Allergan Find an Alternative To Valeant?

Valeant has made a bold bid for Allergan, but Allergan does not appear too happy to see it.

Apr 23, 2014 at 2:30PM

No one will accuse Valeant (NYSE:VRX) CEO Mike Pearson of lacking boldness. He has laid out a strategy for turning Valeant into one of the largest pharmaceutical/med-tech companies in the world and has proven more than willing to turn to bold M&A moves to make it happen. Valeant's latest move is far and away the largest – a $47 billion bid (at the time of the offer) for Allergan (NYSE:AGN) – but the target's acceptance is hardly a sure thing and the company's views about the pharma industry may give investors reason for pause regarding the long-term strategy.

A large bid for a prime target
Allergan has been regarded as an appealing acquisition target for some time, and Valeant has stepped up with a $47 billion cash and stock offer. The initial offer is $48.30 in cash per Allergan share and 0.83 shares of Valeant, valuing Allergan at $158 at the time of the offer. Valeant is offering Allergan shareholders a degree of choice on the cash/stock mix, though the final weightings are subject to proration, and Valeant contemplates Allergan shareholders owning about 43% of the resulting company.

Making this bid a little more unusual, Valeant is teaming up with Bill Ackman's Pershing Square. Pershing Square has already acquired 9.7% of Allergan's shares and supports Valeant's bid, including a commitment to accept 100% stock in the bid.

While Allergan's shares had run up in anticipation of a bid, the 15% premium to the prior high is not as robust as might have been expected. With Allergan decidedly cool to Valeant's overtures (the company has reportedly been rebuffing Valeant for 18 months), it is not unsurprising to see speculation that Valeant will have to sweeten the bid to seal a deal.

Ample synergies on tap
Valeant believes that Allergan is ripe for cost cuts that will drive value for Valeant shareholders. Valeant management has laid out a case for strong (25%-plus) pro forma accretion, predicated on $2.7 billion in cost cuts and the significantly lower tax rate Valeant enjoys.

Valeant acknowledges that certain divestitures will be necessary to get approval, including parts of the Medicis aesthetics business. Even so, the company sees substantial synergies in the aesthetics, dermatology, and ophthalmology assets of Allergan. Botox is a major high-value, wide-moat asset for Allergan, but I would also observe that Allergan brings a fairly rich portfolio of glaucoma assets to a Valeant ophthalmology business that is very, very weak in that large space (roughly one-third of the ophthalmology drug market).

Potential flies in the ointment
There are at least a couple of issues that could get in the way of a successful deal here. First, Allergan is not exactly bursting with joy to see this offer from Valeant. The company has apparently rebuffed Valeant before and Allergan's board has adopted a one-year poison pill plan that effectively blocks an investor from acquiring more than 10% of the shares and/or taking an offer directly to Allergan's shareholders.

Second, and perhaps of more concern to long-term Valeant shareholders, is the company's attitude regarding R&D. Of the $2.7 billion in targeted synergies from the deal, about $900 million would come from R&D and Valeant basically proposes to gut Allergan's R&D efforts. Valeant's presentation went out of its way to show management's apparent disdain for pharmaceutical R&D, pointing out 35 clinical trial failures, declining R&D/pipeline investment returns, and so on.

I believe it is inarguable that pharmaceutical R&D has gotten more expensive and drug development has become more challenging. The alternative, though, is to simply become an M&A and sales operation, acquiring drugs and devices developed by other companies and running a bare-bones internal R&D effort. There's certainly room for differing opinions here; Forest Labs did pretty well with an in-licensing/acquisition philosophy, but I believe it will be quite a bit harder for a company of Valeant's contemplated size to be competitive with a weak internal R&D program.

Will Allergan look for help?
Allergan has options if it really does not want to become part of Valeant. Finding a "white knight" acquirer is certainly a possibility. Johnson & Johnson (NYSE:JNJ) has sizable eye care and skin care businesses, though it has not been as active in ophthalmology and dermatology and there would need to be divestitures in the breast implant business. Johnson & Johnson could also achieve meaningful SG&A leverage without gutting Allergan's R&D efforts. AstraZeneca could also be an option if the company wishes to avoid an offer from Pfizer, particularly as Allergan could leverage AstraZeneca's superior overseas sales leverage.

Allergan could also turn to offense. Acquiring either Shire or Teva would pave the way for a tax inversion transaction, and there would be some synergy with Shire's ophthalmology assets and Teva's global sales infrastructure.

The bottom line
I appreciate Valeant's bold vision of itself as a major up-and-comer in the pharma/med-tech space, but the company's attitude has given me reason for pause in the past, and its view of Allergan's R&D effort only intensifies those concerns. Maybe Valeant is right in its view that pharma R&D spending is increasingly wasteful, but it is my position that long-term success in this sector is predicated on a strong R&D effort.

For Allergan's part, it is hard to argue that Valeant isn't offering good value. Allergan's wish to see its business grow and thrive may well be an unresolvable conflict with Valeant's goals, but ultimately it is the board's responsibility to do right by its shareholders and maximize the value for them.

3 stocks poised to be multi-baggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and Valeant Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson and Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information